Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Madrigal Pharmaceuticals, Inc. - Common Stock
(NQ:
MDGL
)
582.34
-1.39 (-0.24%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 31, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Madrigal Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Why These 7 Healthcare Stocks Could Soar in 2023
↗
January 02, 2023
These healthcare stocks to buy are trading at a hefty discount and are poised to deliver robust returns in 2023.
Via
InvestorPlace
5 Top Stocks for January
↗
January 01, 2023
Now is the time to begin crafting your watch list for 2023.
Via
The Motley Fool
Singing Machine, Blue Apron, Camber Energy And More Short Squeeze Candidates That Could Soar This Week
↗
December 27, 2022
Potential short squeeze plays gained steam in 2021 and have continued through 2022, with new traders looking for the next huge move. High short interest and a high cost to borrow are among the common...
Via
Benzinga
This Stock That Tripled in 2022 Could Rocket Even Higher in 2023
↗
December 26, 2022
Potential suitors with heaps of cash to spend are lining up to get a closer look at this company's results.
Via
The Motley Fool
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,800 Today
↗
December 23, 2022
Via
Benzinga
Analyst Ratings for Madrigal Pharmaceuticals
↗
December 20, 2022
Via
Benzinga
Stock Market Falls Sharply Again As Tesla Dives, Micron Hits Chips; Nike, FedEx Strong: Weekly Review
↗
December 23, 2022
The market uptrend is under pressure.
Via
Investor's Business Daily
Universal Health Services, Madrigal Pharmaceuticals And These Overbought Majors In The Healthcare Sector
↗
December 23, 2022
The most overbought stocks in the healthcare sector presents an opportunity to go short on these overvalued companies.
Via
Benzinga
Why Madrigal Pharmaceuticals Was a Top Stock This Week
↗
December 23, 2022
Biotech bulls stampeded the company following its latest clinical update.
Via
The Motley Fool
7 Drug Stocks That Will Soar in 2023
↗
December 22, 2022
These drug stocks to buy look poised to generate huge profits for investors in 2023 and in subsequent years.
Via
InvestorPlace
Earnings Optimism Puts Wind In Wall Street's Sails
↗
December 21, 2022
The major indexes are extending their rally off a mid-December losing streak.
Via
Talk Markets
Why Did Viking Therapeutics Stock Skyrocket
December 21, 2022
VKTX stock is young but strong and they have excellent potential, particularly following successful trial results from Madrigal Pharma's recent drug trial.
Via
MarketBeat
Top M&A Target: Madrigal Pharmaceuticals Could Be Next After Successful NASH Data, Analyst Says
↗
December 20, 2022
Via
Benzinga
Madrigal Pharmaceuticals Gets Price Target Bumps By Analysts Following Successful NASH Study
↗
December 20, 2022
Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) announced positive topline results from the pivotal Phase 3 MAESTRO-NASH biopsy trial of resmetirom. Madrigal Pharmaceuticals shares jumped 268.1% to close...
Via
Benzinga
Peering Into Madrigal Pharmaceuticals's Recent Short Interest
↗
December 20, 2022
Madrigal Pharmaceuticals's (NASDAQ:MDGL) short percent of float has risen 3.82% since its last report. The company recently reported that it has 2.16 million shares sold short, which is 15.49% of all...
Via
Benzinga
Tesla To $285? Here Are 10 Other Price Target Changes For Tuesday
↗
December 20, 2022
Wells Fargo raised Ross Stores, Inc. (NASDAQ: ROST) price target from $120 to $135. Wells Fargo analyst Ike Boruchow maintained an Overweight rating on the stock. Ross Stores shares fell 0.9% to close...
Via
Benzinga
Here's How An Options Trader Made $5.5 Million In One Day
↗
December 20, 2022
Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) shares rose sharply on Monday after the company announced positive topline results from the pivotal Phase 3 MAESTRO-NASH (fatty liver disease)
Via
Benzinga
Tesla, Amazon, Apple, Madrigal, Walt Disney: Why These 5 Stocks Are Drawing Investors' Attention Today
↗
December 19, 2022
Major Wall Street indices closed in the red on Monday as investor optimism on the much-anticipated Santa Claus rally began to fade over fears of recession gaining momentum.
Via
Benzinga
Healthcare Portfolio Is Doing Well But Biotech Stocks Are Mired In Macro
↗
December 19, 2022
The biotech sector has not done well in 2022 despite some strong runs. Small and mid-cap stocks are more “risk-off’ with interest rates rising and sentiment waning.
Via
Talk Markets
Madrigal Pharmaceuticals (NASDAQ: MDGL) Reports Impressive Topline Results from Phase 3 Trial of Resmetirom to Treat NASH and Liver Fibrosis
December 19, 2022
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development
Via
Spotlight Growth
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
↗
December 19, 2022
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.
Via
Benzinga
Dow Struggles To Maintain Morning Gains
↗
December 19, 2022
This morning's rally was short-lived, and by midday, the major indexes were trading back in the red amid looming recession anxieties.
Via
Talk Markets
12 Health Care Stocks Moving In Monday's Intraday Session
↗
December 19, 2022
Via
Benzinga
Why Madrigal Pharmaceuticals Stock Is Crushing It Today
↗
December 19, 2022
The company reported stellar late-stage clinical trial results for its experimental NASH (nonalcoholic steatohepatitis) drug.
Via
The Motley Fool
Madrigal Pharmaceuticals, Cerevel Therapeutics And Some Other Big Stocks Moving Higher On Monday
↗
December 19, 2022
U.S. stocks traded mixed, with the Nasdaq Composite dropping around 90 points on Monday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Tesla's Bouncing, but This Nasdaq Stock Tripled Monday Morning
↗
December 19, 2022
Good news can come in different forms.
Via
The Motley Fool
Why Is Viking Therapeutics (VKTX) Stock Up 67% Today?
↗
December 19, 2022
Viking Therapeutics (VKTX) stock is taking off on Monday with heavy trading without any news from the biopharmaceutical company.
Via
InvestorPlace
AJRD Stock Alert: What to Know as L3Harris Technologies Acquires Aerojet Rocketdyne
↗
December 19, 2022
Aerojet Rocketdyne (AJRD) stock is on the move today as investors react to a $4.7 billion deal with L3Harris Technologies (LHX).
Via
InvestorPlace
Madrigal Pharmaceuticals Stock Is Up 200% In One Day, Here's Why
December 19, 2022
Madrigal Pharmaceuticals announced positive results for a major clinical trial and shares are up more than 200% because of it.
Via
MarketBeat
Why Viking Therapeutics Stock Is Moving Alongside Madrigal Pharmaceuticals Shares Today
↗
December 19, 2022
Viking Therapeutics Inc (NASDAQ: VKTX) shares are trading higher Monday, in sympathy with Madrigal Pharmaceuticals Inc (NASDAQ: MDGL), which announced a suc
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.